APA (7th ed.) Citation

Lemech, C., Sun, Y., Nagrial, A., Wu, X., Morris, M., Ning, F., . . . Day, D. (2024). 345MO IBI354 (anti-HER2 antibody-drug conjugate [ADC]) in patients (pts) with advanced solid tumors and breast cancer (BC): Results from a phase I study. Annals of Oncology, 35, S360. https://doi.org/10.1016/j.annonc.2024.08.293

Chicago Style (17th ed.) Citation

Lemech, C., et al. "345MO IBI354 (anti-HER2 Antibody-drug Conjugate [ADC]) in Patients (pts) with Advanced Solid Tumors and Breast Cancer (BC): Results from a Phase I Study." Annals of Oncology 35 (2024): S360. https://doi.org/10.1016/j.annonc.2024.08.293.

MLA (9th ed.) Citation

Lemech, C., et al. "345MO IBI354 (anti-HER2 Antibody-drug Conjugate [ADC]) in Patients (pts) with Advanced Solid Tumors and Breast Cancer (BC): Results from a Phase I Study." Annals of Oncology, vol. 35, 2024, p. S360, https://doi.org/10.1016/j.annonc.2024.08.293.